Amsterdam UMC proudly presents new spin-off Kling BioTherapeutics

Kling BioTherapeutics is a newly-formed Amsterdam UMC spin-off that is discovering and developing innovative antibody and antibody-derived drugs to treat cancer and infectious disease patients. With its lead program preparing to enter human clinical trials, Kling is well positioned to become an immuno-oncology biotech leader with a novel¬†discovery¬†platform and a robust pipeline of first in … Continue reading Amsterdam UMC proudly presents new spin-off Kling BioTherapeutics